Lupin announced its unaudited financial results for the quarter and half-year ended September 30, 2025. The Board of Directors approved these results in a meeting held on November 6, 2025. Key highlights include revenue from operations of ₹70,475.1 million and a profit of ₹14,848.3 million after tax for the quarter.
Financial Performance
Lupin Limited has released its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2025. The results were approved by the Board of Directors on November 6, 2025.
Key Financial Figures (Consolidated)
For the quarter ended September 30, 2025:
- Revenue from operations: ₹70,475.1 million
- Total Income: ₹71,375.1 million
- Profit after tax: ₹14,848.3 million
For the six months ended September 30, 2025:
- Revenue from operations: ₹133,158.5 million
- Total Income: ₹134,848.9 million
- Profit after tax: ₹27,062.9 million
Segment-Wise Revenue (Quarterly)
- Pharmaceuticals: ₹70,103.2 million
- Others: ₹376.8 million
Exceptional Items
During the quarter, Lupin transferred its Over the Counter (‘OTC’) and API R&D business in India to its wholly owned subsidiaries resulting in a gain of ₹6,589.6 million and ₹37.2 million respectively.
Dividend
As approved by the members on August 11, 2025, a final dividend of ₹12 per equity share was disbursed on August 14, 2025, totaling ₹5,481.0 million.
Source: BSE
